Northwest Biotherapeutics, Inc., a biotechnology company, focuses on developing personalized immune therapies for cancer. The company develops DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Its lead product candidate is the DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, that has completed Phase I clinical trials to treat inoperable solid tumors, as well as a range of types of cancers. Northwest Biotherapeutics, Inc. was founded in 1996 and is headquartered in Bethesda, Maryland. Show more

Location: 4800 Montgomery Lane, Bethesda, MD, 20814, United States | Website: https://www.nwbio.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

370.6M

52 Wk Range

$0.17 - $0.48

Previous Close

$0.25

Open

$0.25

Volume

2,919,841

Day Range

$0.24 - $0.25

Enterprise Value

429.1M

Cash

4.316M

Avg Qtr Burn

-11.13M

Insider Ownership

7.30%

Institutional Own.

0.05%

Qtr Updated

06/30/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.